We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01678053
Recruitment Status : Withdrawn (Was not able to recruit patients for randomization.)
First Posted : September 3, 2012
Last Update Posted : March 28, 2017
Information provided by (Responsible Party):
Phillip Song, MD, Massachusetts Eye and Ear Infirmary

Brief Summary:
Vocal process granulomas are inflammatory masses caused in part by vocal trauma that arise in the posterior aspect of the vocal folds and result in throat pain, difficulty swallowing, hoarseness, and globus sensation. Antireflux therapy treats most granulomas, but many are recalcitrant to this therapy or take months to years to resolve. Botulinum toxin injection into the thyroarytenoid muscle has been effectively employed for recalcitrant granuloma, but causes significant voice loss, occasional difficulty swallowing and, in our clinical experience, is associated with significant recurrence. The investigators propose injecting another muscle in the larynx called the interarytenoid muscle with botulinum toxin type A to maintain the benefit of injection with less loss of voice. The investigators have shown the effectiveness of this treatment in a small, retrospective analysis.

Condition or disease Intervention/treatment Phase
Contact Ulcer of Vocal Folds Granuloma of Vocal Cords Granuloma, Laryngeal Granuloma Drug: onabotulinumtoxinA Drug: omeprazole (proton pump inhibitor) Phase 2

Detailed Description:

Vocal fold granulomas may be due to reflux, voice trauma, intubation, multiple or unknown etiologies. Regimens of voice therapy and anti-reflux medications have show resolution rates varying from 38% to 100%, with recurrence rates of 15-20%, and up to 50-92% in surgical-operated on recalcitrant granulomas. Nasri and colleagues first proposed thyroarytenoid botulinum toxin type A (BOTOX) injections for vocal fold granulomas with success. They posited that the chemically paralyzed muscle would result in limited contact at the site of the granuloma, allowing for healing. Damrose and Damrose further showed that thyroarytenoid BOTOX injections were effective in treating recalcitrant vocal fold granulomas. Both of the above groups noted hoarseness as an expected side effect. Pham and colleagues showed complete resolution of granulomas in 2-8 weeks after treatment with thyroarytenoid BOTOX injections. This was compared to mean granuloma resolution of 5.7 months proton pump inhibitor therapy alone. The investigators reviewed eight patients treated for recalcitrant vocal fold granuloma at Mass Eye and Ear with interarytenoid BOTOX injections and found no serious adverse effects and complete response in seven cases. The investigators now seek to compare interarytenoid BOTOX injections to standard anti-reflux therapy alone to see if the addition of IA Botox injections improves response rates at 3 months. The investigators chose this timeframe since 86% of granulomas treated in our retrospective study had resolved 3 months after initiation of treatment compared to 25% of granulomas treated with medical management.

The investigators will not include a Thyroarytenoid injection arm in this study as this technique has not been useful in our clinical experience.

For those who consent, a Voice Handicap Index survey (6 - see attached) will be completed. Participants will then be randomized to undergo only medical therapy with omeprazole (40mg by mouth twice daily ) or an interarytenoid BOTOX injection followed by the same reflux regimen. Randomization will be performed by the Tufts online randomization plan, which may be found at: http://www.tufts.edu/~gdallal/PLANDOC.HTM. This program generates a random order in which participants will be enrolled in either of the two arms of the study.

The injection will consist of 10 units of botulinum toxin injected into the interarytenoid muscle under fiberoptic visualization. All participants will remain on the PPI therapy for the duration of the study. Participants will receive prescriptions for PPI medication from the attending Laryngologist and participants will then be responsible for acquiring and taking their medications.

Injections will be performed per standard MEEI Laryngology protocol for interarytenoid BOTOX injection. Participants will then be evaluated at 1.5 months, 3 months and 6 months with fiberoptic examination as well as Voice Handicap Index & Reflux Symptom Index. Participants in the medication only arm who continue to have a granuloma at 3 months will receive a BOTOX injection. They will be re-evaluated 3 months after the injection. Examinations will be recorded and reviewed by blinded reviewers.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma
Study Start Date : September 2012
Primary Completion Date : January 2015
Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox
U.S. FDA Resources

Arm Intervention/treatment
Experimental: PPI and BOTOX
onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
Drug: onabotulinumtoxinA
Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
Other Names:
  • Botulinum toxin A
Drug: omeprazole (proton pump inhibitor)
Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
Other Name: omeprazole
Proton pump inhibitor only
omeprazole 40mg po bid for 3 months(standard of care)
Drug: omeprazole (proton pump inhibitor)
Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
Other Name: omeprazole

Primary Outcome Measures :
  1. Complete resolution of vocal fold granuloma [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Voice Handicap Index score [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults age 18 years old and older with vocal fold granulomas
  • willing to attend all follow-up appointments

Exclusion Criteria:

  • pregnant females
  • woman who are nursing
  • minors and other patients unable to give informed consent
  • patients taking Plavix
  • patients with:
  • impaired laryngeal motion as the result of neurological impairment
  • vocal fold immobility
  • pre-existing oropharyngeal swallowing problems
  • history of radiation therapy
  • history of aspiration pneumonia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01678053

United States, Massachusetts
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Phillip Song, MD
Principal Investigator: Phillip Song, M.D. Massachusetts Eye and Ear Infirmary

Responsible Party: Phillip Song, MD, Otolaryngologist, Massachusetts Eye and Ear Infirmary
ClinicalTrials.gov Identifier: NCT01678053     History of Changes
Other Study ID Numbers: 11-090H
First Posted: September 3, 2012    Key Record Dates
Last Update Posted: March 28, 2017
Last Verified: March 2017

Keywords provided by Phillip Song, MD, Massachusetts Eye and Ear Infirmary:
Botulinum Toxins, Type A

Additional relevant MeSH terms:
Pressure Ulcer
Granuloma, Laryngeal
Lymphoproliferative Disorders
Lymphatic Diseases
Pathologic Processes
Skin Ulcer
Skin Diseases
Granuloma, Respiratory Tract
Respiratory Tract Diseases
Laryngeal Diseases
Respiratory Insufficiency
Respiration Disorders
Otorhinolaryngologic Diseases
Botulinum Toxins
Botulinum Toxins, Type A
Proton Pump Inhibitors
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Neuromuscular Agents